New York-based Bristol-Myers Squibb Co. announced that its $7.8 billion acquisition of Wilmington, DE-based DuPont Pharmaceuticals Co. from DuPont is complete. The acquisition, which was announced on June 7, closed on October 1.
New York-based Bristol-Myers Squibb Co. announced that its $7.8 billion acquisition of Wilmington, DE-based DuPont Pharmaceuticals Co. from DuPont is complete. The acquisition, which was announced on June 7, closed on October 1.
"The acquisition of DuPont Pharma will make Bristol-Myers Squibb an even stronger pharmaceutical company," said Peter R. Dolan, chairman and chief executive officer of Bristol-Myers Squibb. "It will enable us to play a greater leadership role, particularly in the areas of virology and cardiovascular diseases, where there is a pressing need to expand treatments and find new and better therapies. Our combined research and development pipelines and truly innovative discovery efforts will usher in medical advances for years to come in many areas of great human need."
With this acquisition, Bristol-Myers Squibb gains several products, including Sustiva⢠(efavirenz), a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV/AIDS; Coumadin® (warfarin sodium tablets, USP), an oral blood anticoagulant; and Cardiolite® (kit for the preparation of Technetium Tc99m Sestamibi for injection), a cardiovascular medical imaging agent. Bristol-Myers Squibb also gains an R&D pipeline that includes compounds in five therapeutic areas - virology, cardiovascular diseases, inflammatory diseases, cancer and disorders of the central nervous system.
Under the terms of the agreement, Bristol-Myers Squibb paid $7.8 billion in cash for DuPont Pharma. As a result of the transaction, the company expects to record a one-time, in-process R&D write-off and restructuring liability in the range of $2 billion to $3 billion. PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.